ArticleGastroenterology & hepatology2012
Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.
Article in Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Evaluation of the efficacy of polyethylene glycol in combination with different doses of linaclotide in a fractionated bowel preparation for colonoscopy: a prospective randomized controlled study.International journal of colorectal disease · 2024Trial
- Oxalate nephropathy precipitated by linaclotide in a high-risk patient.Clinical nephrology. Case studies · 2025Article
- Constipation in ulcerative colitis: pathophysiology and practical management.Frontline gastroenterology · 2021Article
- Epithelial-Neuronal Communication in the Colon: Implications for Visceral Pain.Trends in neurosciences · 2020Review
- Understanding and Managing IBS and CIC in the Primary Care Setting.Gastroenterology & hepatology · 2018Article
- Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide.International journal of general medicine · 2017Review
- Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?Annals of gastroenterology · 2017Review
- Constipation in adults: diagnosis and management.Current treatment options in gastroenterology · 2014Article
- Update in diagnosis and management of irritable bowel syndrome.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-1 2% of the US population meet the diagnostic criteria for IBS, and 1 5% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, first-in-class medication for the treatment of chronic constipation and constipation-predominant IBS.
Indexed as
Identifiers
24683372PMC3969007W2104008873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.